J&J paid Numab Therapeutics $1.25 billion upfront for the asset in 2024 based on the belief that its dual mechanism of action ...

After getting the crucial first-mover advantage with an FDA approval for a weight loss pill, Novo looks to win the market ...

The fierce rivalry between Novo Nordisk and Eli Lilly is alive and well, as the two companies are expected to face off with ...

As 2026 begins, a slate of high-stakes clinical readouts—from a pivotal study of Novartis’ cardiovascular candidate ...

After a tumultuous year, experts call for stability while anticipating the first fruits of policies intended to expedite ...

One way Takeda lives out its values is by striving to ensure that patients are aware of and can access the company’s clinical ...